Advanced non-small-cell lung cancer (aNSCLC) harboring activating epidermal growth factor receptor (EGFR) mutation benefits from oral tyrosine-kinase inhibitors (TKIs) such as gefitinib, erlotinib, afatinib and osimertinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.